Role of Esaxerenone in the Integrated Management of Hypertension and Kidney Disease

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), is emerging as a promising therapeutic agent in the integrated management of hypertension and kidney disease. By selectively inhibiting mineralocorticoid receptors, esaxerenone offers potent antihypertensive effects while demonstrating significant renoprotective benefits in clinical trials. This review synthesizes recent evidence regarding esaxerenone's pharmacological mechanisms, clinical efficacy, safety profile, and its place in current treatment paradigms, offering practical insights for clinicians managing patients with overlapping cardiovascular and renal comorbidities.

Introduction

Hypertension and chronic kidney disease (CKD) are interlinked clinical entities that significantly contribute to cardiovascular morbidity and mortality worldwide. Despite advances in antihypertensive therapy, optimal blood pressure (BP) control and renal protection remain challenging, especially in patients with concomitant CKD. Mineralocorticoid receptor antagonists (MRAs) have shown efficacy in reducing BP and providing organ protection, but their use has been limited by adverse effects, notably hyperkalemia. Esaxerenone, a next-generation non-steroidal MRA, has been developed to address these limitations. This review explores the integrated role of esaxerenone in managing hypertension and kidney disease, focusing on recent clinical evidence and practical guidance for healthcare professionals.

Epidemiology / Disease Burden

Hypertension affects over 1.2 billion individuals globally and is the leading modifiable risk factor for cardiovascular disease and CKD. The prevalence of CKD is estimated at 10-15% among adults, with hypertension contributing to both the onset and the progression of renal impairment. The coexistence of these conditions amplifies the risk of adverse cardiovascular outcomes, end-stage renal disease, and premature death. Epidemiological data indicate that effective BP control can significantly slow CKD progression and reduce cardiovascular events, underscoring the need for integrated therapeutic approaches.

Pathophysiology

The pathogenesis of hypertension and CKD is multifactorial, involving dysregulation of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, inflammation, and oxidative stress. Mineralocorticoid receptors (MRs), primarily activated by aldosterone, play a pivotal role in sodium retention, vascular remodeling, fibrosis, and inflammation. In CKD and hypertension, inappropriate MR activation exacerbates glomerular and tubulointerstitial injury, contributing to progressive nephron loss and increased BP. Selective MR blockade can disrupt these deleterious pathways, offering both antihypertensive and renoprotective effects.

Risk Factors

Common risk factors for developing hypertension and CKD include advanced age, obesity, diabetes mellitus, genetic predisposition, high sodium intake, and chronic inflammation. Persistent RAAS activation is a central mechanism, leading to fluid retention, vascular fibrosis, and increased sympathetic activity. Patients with diabetes or metabolic syndrome are particularly susceptible to aldosterone-mediated renal injury and hypertension, highlighting the need for targeted therapies addressing MR overactivity.

Clinical Features

Hypertension is often asymptomatic until complications arise, while CKD may present with proteinuria, declining glomerular filtration rate (GFR), and electrolyte imbalances. In advanced stages, patients may experience edema, anemia, and cardiovascular symptoms. Uncontrolled hypertension accelerates CKD progression, and vice versa, creating a vicious cycle of end-organ damage. Early identification and comprehensive management are critical to prevent irreversible complications.

Diagnosis

Diagnosis of hypertension relies on repeated BP measurements, preferably with ambulatory or home monitoring to exclude white-coat effect. CKD diagnosis is based on estimated GFR, albuminuria/proteinuria assessment, and renal imaging when indicated. Laboratory evaluation should include serum electrolytes, creatinine, urinary sediment, and assessment of secondary causes. Risk stratification incorporates cardiovascular risk profiling, assessment of target organ damage, and identification of modifiable factors.

Treatment & Management

Optimal management of hypertension and CKD requires a multifaceted approach: lifestyle modification, dietary sodium restriction, and pharmacologic intervention with RAAS inhibitors (ACE inhibitors or ARBs), diuretics, calcium channel blockers, and beta-blockers as indicated. MRAs are recommended in resistant hypertension and in patients with proteinuric CKD or heart failure. Esaxerenone, as a non-steroidal MRA, offers potent and selective MR blockade with a favorable safety profile, making it an attractive option for integrated management. Clinical trials have demonstrated that esaxerenone significantly lowers BP, reduces albuminuria, and slows renal function decline compared to placebo and even to conventional MRAs, with a lower incidence of hyperkalemia.

Recent Advances / Emerging Therapies

Esaxerenone represents a significant advancement in MRA therapy, with pharmacokinetic and pharmacodynamic properties that confer high MR selectivity, minimal off-target effects, and predictable metabolism. Recent phase 3 trials (e.g., ESAX-HTN, ESAX-DN) have shown that esaxerenone effectively lowers systolic and diastolic BP, reduces urinary albumin excretion, and is well tolerated in patients with hypertension and/or diabetic nephropathy. Emerging data suggest that esaxerenone can be safely combined with RAAS inhibitors, further enhancing renoprotective effects while minimizing hyperkalemia risk through careful patient selection and monitoring.

Guideline Recommendations

Recent hypertension and CKD guidelines emphasize individualized therapy, prioritizing RAAS blockade and the use of MRAs in resistant hypertension or proteinuric CKD. Japanese Society of Hypertension and KDIGO guidelines have recognized esaxerenone as a valuable addition to the therapeutic arsenal, particularly for patients with suboptimal response to conventional agents or those at risk of steroidal MRA-related side effects. Dose titration, regular monitoring of serum potassium and renal function, and patient education remain pivotal for safe and effective use.

Conclusion

Esaxerenone is a potent, selective, non-steroidal MRA that bridges an important therapeutic gap in the integrated management of hypertension and kidney disease. Its efficacy in lowering BP and reducing proteinuria, along with a favorable safety profile, positions it as a first-line adjunct in patients with resistant hypertension or CKD, especially when conventional MRAs are contraindicated or not tolerated. Continued clinical experience and real-world data will further define its long-term role in reducing cardiorenal morbidity and mortality, reinforcing its significance in contemporary guideline-directed management.